Ken VanLuvanee, President and CEO“Many of our clients are breaking new scientific and regulatory ground every day and are doing that with compressed timelines and constrained budgets. We cannot simply pull out the playbook and execute a generic strategy,” says Ken VanLuvanee, president and CEO, Facet Life Sciences. “We work with clients to understand the unique nature of their drug, biologic, device, gene therapy, or combination product to develop the most efficient, scientifically sound, and data-driven arguments to present to FDA.”
When engaging with clients, Facet usually begins with a gap analysis, an independent assessment of what the sponsor has done to date in the context of their stated goals. They evaluate whether additional work is needed to bridge existing gaps, then help set nonclinical, CMC, and clinical development plans, as needed, to achieve regulatory and corporate milestones in a fast and efficient way.
The company also provides recommendations, guidance, and support for FDA interactions (meetings, correspondence, etc), as well as advice and support to increase a product’s value via what Facet calls “regulatory assets” (for example, Breakthrough Therapy Designation, Fast Track, or Orphan Designation).
After reviewing the data, Facet indicated that the sponsor likely had enough data (if properly presented) to approach FDA for marketing approval. FDA agreed with Facet’s proposed arguments, enabling the sponsor to proceed directly to marketing application. The application was approved in near-record time, allowing the sponsor to be on market years before they expected to even complete their Phase 3 program.
Facet’s approach presents aggressive yet scientifically sound arguments to FDA that have, at times, saved years and millions of dollars from clients’ initial development expectations. For example, Facet worked with a company that presented them with a novel product and a bundle of data collected both in and ex-U.S. as part of investigator-led studies. The sponsor’s stated goal was to obtain agreement on a Phase 3 program with FDA based on the data.
We work with clients to understand the unique nature of their drug, biologic, device, gene therapy, or combination product to develop the most efficient, scientifically sound, and data-driven arguments to present to FDA
Facet Life Sciences sees each program as unique and brings real-world experience to clients. The company is comprised of scientists who are experienced, creative, and not tied to how development has always been done. They seek collaborative relationships with FDA and clients based on scientific consensus rather than a cookie-cutter approach to generating and creating regulatory assets. Facet Life Sciences also understands the needs of small business clients and the importance of non-scientific milestones like board meetings, investor sessions, and industry conferences.
“We are genuinely excited to have worked on programs that have made it to patients in need due to our approach,” says VanLuvanee.
Navigating Regulatory Complexity in Emerging Biotech Development
Regulatory strategy in life sciences has shifted from a compliance exercise to a defining factor in whether a therapy reaches patients at all. Executives overseeing development programs face a landscape where evolving FDA expectations, compressed funding cycles and heightened scrutiny around evidence generation intersect. Traditional development models, built for large pharmaceutical organizations with extensive resources, often fail to translate to emerging biotech environments where capital efficiency and speed carry equal weight to scientific rigor.
Uncertainty in regulatory pathways has become a central challenge. Agencies continue to refine guidance across biologics, personalized therapies and novel modalities, creating ambiguity in how evidence packages should be constructed. Early-stage companies, in particular, struggle to determine how much data is sufficient at each milestone. Overbuilding evidence can delay timelines and exhaust capital, while under-preparing risks rejection or costly rework. The consequence is a persistent tension between caution and progress that requires experienced judgment rather than procedural adherence.
Effective regulatory leadership begins with clarity around business intent. Development pathways differ significantly depending on whether a company aims to secure early proof of concept for partnership or carry a product through full approval and commercialization. Aligning regulatory decisions to that objective ensures that every study, interaction and submission contributes directly to the intended outcome rather than following a generalized pathway. This alignment reduces unnecessary work and avoids missteps that cascade into later stages of development.
Early-stage decision-making holds disproportionate influence over program success. Conversations with regulators, trial design choices and endpoint selection create downstream implications that can alter timelines by years. Programs that engage in disciplined planning at inception are better positioned to avoid redundant studies and reposition quickly when data evolves. The ability to interpret emerging results and adjust strategy without compromising regulatory acceptance has become a defining capability in modern development.
Scientific narrative also plays a critical role. Regulatory agencies ultimately evaluate whether a therapy is safe, effective and meaningful for patients. Translating complex data into a coherent argument that demonstrates these outcomes requires more than technical execution. It demands an understanding of how evidence is perceived, how risk is contextualized and how to present findings in a way that aligns with regulatory expectations. Companies that succeed in this area tend to focus not only on generating data but on ensuring that the data clearly supports a compelling case for approval.
Continuity across development stages further distinguishes effective programs. Fragmentation between regulatory, clinical and commercial planning often leads to misalignment, particularly when commercialization considerations are deferred. Early visibility into market positioning, patient populations and payer expectations informs better scientific and regulatory choices. Organizations that integrate these perspectives from the outset are more likely to pursue development paths that balance feasibility, value and long-term viability.
Facet Life Sciences exemplifies this integrated approach by focusing on emerging biotech companies and aligning regulatory strategy closely with business objectives. It brings an experienced team that guides clients through regulatory, clinical and manufacturing considerations while emphasizing efficient evidence generation. Its approach centers on identifying opportunities to streamline development, often enabling clients to avoid unnecessary studies and reduce both time and cost. The firm supports programs from early development through submission while maintaining continuity through data interpretation and strategic adjustments. By combining regulatory insight with scientific framing and commercial awareness, it positions itself as a strong partner for companies aiming to advance therapies efficiently without compromising quality.
...Read more
